CUBE vs CUE
CubeSmart (CUBE) versus Cue Biopharma (CUE) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. CUE currently screens at market cap $59.5M.
Not investment advice. Open the CUBE and CUE stock pages for the full models.
Not investment advice.